Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.00 – $1.47
45% from low
Exchange
OTC Link
OS
Borrow rate
5.52%
Hard to borrow
CANNARA BIOTECH INC
No one on the platform currently holds LOVFF.
No tracked institution reports a position in LOVFF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-02-13 | 1-for-10reverse |
No one on the platform has traded LOVFF yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$LOVFF only downside is the P/E is already at 14.75 so its not far from fair value. Still room to grow though
View on StockTwits ↗https://nfne.ws/289140 $LOVFF $LOVE.TSX @btvceoclips #CEOClips #CEOInterview #CompanyFeature #OTC #OTCMarkets #OTCStocks #TSX #Investing
View on StockTwits ↗Cannabis Producer Moves to the TSX as Analyst Flags Major Expansion Potential https://ow.ly/qZSR50YrsWE Cannara Biotech Inc. ($LOVE.TO; $LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange on March 2 after graduating from the TSX Venture Exchange. Atrium Research initiated coverage with a BUY rating and CA$3.00 target, citing best-in-class EBITDA margins of 29%.
View on StockTwits ↗Record Profits, a Vape Market Landgrab, and a CA$250M Facility Bought for CA$27M https://ow.ly/twTw50YpLcg Atrium Research initiated coverage on Cannara Biotech Inc. ($LOVE.TO; $LOVFF:OTCQX; BCB0:FSE), citing the company's dominant position in Quebec's new vape category, best-in-class EBITDA margins of 29%, and a capital-efficient expansion path at its Valleyfield facility that could unlock 100,000 kg of annual production capacity by FY30.
View on StockTwits ↗$LUFFF $CRON $HITI $LOVFF $DBCCF TD Cowen initiates: Big bank just dropped fresh coverage on the Canadian cannabis space; calling it structurally improved with better pricing, scaled players finally cash-flow positive, and valuations still dirt cheap. Feels like the sector's quietly setting up for a re-rating. Who's feeling optimistic?
View on StockTwits ↗Interview: Cannara CFO Nicholas Sosiak - Earnings, Expansion Pans, AI & More #CannaraBiotech, #LOVE, #LOVFF, #Cannara, $LOVE, $LOVFF https://youtu.be/jF-RQBL1VKM
View on StockTwits ↗$LOVFF Very exciting if LOVE.V can break $1.90 CDN resistance
View on StockTwits ↗@Riskyybiznazz I worked in the industry at the beginning of legalization. I followed these companies for years. I invested in many of them. I continue to follow them. I follow prominent names on LinkedIn that continue to analyze the business model. One of the only profitable companies right now is $LOVFF I'm not ignorant.
View on StockTwits ↗$LUFFF $TLRY $AVTBF $LOVFF $CGC “The Company stands alone in its ability to simultaneously double medical sales and provincial footprint/SKUs while tripling exports, opportunities its public peers exhausted years ago. This convergence of untapped channels positions Herbal Dispatch for the sharpest revenue acceleration in the entire public cannabis sector over the next 24-36 months.”
View on StockTwits ↗$TLRY $LUFFF $AVTBF $LOVFF $CGC All these companies got a % of this chart, up to $100M a month in exports! Expected to reach $150M a month by the end of the year!
View on StockTwits ↗$LUFFF $AVTBF.US $TLRY $LOVFF $CGC All these companies got a % of this chart, up to $100M a month in exports! Expected to reach $150M a month by the end of the year!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.